Comparison of Bcl-2, Bax, and Mcl-1 expression in prognostic subsets of the CLL patient cohort
| . | n . | Bcl-2 (median IQR) . | P* . | Mcl-1 (median IQR) . | P* . | Bax (median IQR) . | P* . |
|---|---|---|---|---|---|---|---|
| Stage | .015 | < .001 | < .001 | ||||
| A | 129 | 15 890 (14 302-18 119) | 1414 (1132-1659) | 1596 (1463-1850) | |||
| B/C | 56 | 16 903 (15 849-18 664) | 1630 (1383-1858) | 1413 (1309-1591) | |||
| LDT | .38 | .01 | .02 | ||||
| Less than 12 | 17 | 16 564 (15 547-18 262) | 1622 (1448-1829) | 1511 (1400-1588) | |||
| More than 12 | 112 | 15 940 (14 306-18 119) | 1390 (1132-1646) | 1601 (1466-1881) | |||
| Not evaluable | 56 | 16 488 (15 611-18 627) | 1605 (1352-1789) | 1436 (1309-1640) | |||
| CD38 | < .001 | < .001 | < .001 | ||||
| 20% or more | 91 | 16 713 (15 646-18 543) | 1627 (1375-1843) | 1468 (1352-1633) | |||
| Less than 20% | 94 | 15 531 (14 020-17 074) | 1343 (1107-1635) | 1615 (1477-1963) | |||
| Genetics | .19 | .09 | .004 | ||||
| 11q−/17p− | 26 | 16 903 (15 313-19 042) | 1648 (1231-1954) | 1415 (1336-1522) | |||
| N/O | 118 | 16 242 (14 757-18 371) | 1503 (1207-1729) | 1588 (1448-1866) | |||
| VH status | .06 | < .001 | .14 | ||||
| 98% or more | 59 | 16 491 (15 429-18 619) | 1632 (1503-1963) | 1475 (1352-1698) | |||
| Less than 98% | 126 | 16 209 (14 374-17 932) | 1401 (1147-1653) | 1578 (1436-1767) | |||
| ZAP-70 | .44 | .003 | .29 | ||||
| 20% or more | 84 | 16 263 (15 241-18 336) | 1576 (1388-1746) | 1485 (1358-1660) | |||
| Less than 20% | 101 | 16 338 (14 332-18 147) | 1362 (1149-1657) | 1596 (1451-1793) |
| . | n . | Bcl-2 (median IQR) . | P* . | Mcl-1 (median IQR) . | P* . | Bax (median IQR) . | P* . |
|---|---|---|---|---|---|---|---|
| Stage | .015 | < .001 | < .001 | ||||
| A | 129 | 15 890 (14 302-18 119) | 1414 (1132-1659) | 1596 (1463-1850) | |||
| B/C | 56 | 16 903 (15 849-18 664) | 1630 (1383-1858) | 1413 (1309-1591) | |||
| LDT | .38 | .01 | .02 | ||||
| Less than 12 | 17 | 16 564 (15 547-18 262) | 1622 (1448-1829) | 1511 (1400-1588) | |||
| More than 12 | 112 | 15 940 (14 306-18 119) | 1390 (1132-1646) | 1601 (1466-1881) | |||
| Not evaluable | 56 | 16 488 (15 611-18 627) | 1605 (1352-1789) | 1436 (1309-1640) | |||
| CD38 | < .001 | < .001 | < .001 | ||||
| 20% or more | 91 | 16 713 (15 646-18 543) | 1627 (1375-1843) | 1468 (1352-1633) | |||
| Less than 20% | 94 | 15 531 (14 020-17 074) | 1343 (1107-1635) | 1615 (1477-1963) | |||
| Genetics | .19 | .09 | .004 | ||||
| 11q−/17p− | 26 | 16 903 (15 313-19 042) | 1648 (1231-1954) | 1415 (1336-1522) | |||
| N/O | 118 | 16 242 (14 757-18 371) | 1503 (1207-1729) | 1588 (1448-1866) | |||
| VH status | .06 | < .001 | .14 | ||||
| 98% or more | 59 | 16 491 (15 429-18 619) | 1632 (1503-1963) | 1475 (1352-1698) | |||
| Less than 98% | 126 | 16 209 (14 374-17 932) | 1401 (1147-1653) | 1578 (1436-1767) | |||
| ZAP-70 | .44 | .003 | .29 | ||||
| 20% or more | 84 | 16 263 (15 241-18 336) | 1576 (1388-1746) | 1485 (1358-1660) | |||
| Less than 20% | 101 | 16 338 (14 332-18 147) | 1362 (1149-1657) | 1596 (1451-1793) |
11q−/17p− indicates any FISH or karyotypic abnormality of 11q or 17p and/or a mutational defect of ATM or p53; N, normal cytogenetics; O, other cytogenetic abnormality than 11q−/17p−.
P values not including “Not evaluable.”